The US FDA (Food and Drug Administration) has approved Sanofi’s Nexviazymefor to treat patients with rare but potentially fatal muscle disorder, Pompe disease. Pompe disease affects 1 in 40,000 Americans and weakens the heart and skeletal muscles caused by an accumulation of glycogen sugar. The French drug maker designed the drug as an injectable enzyme replacement therapy to be administered in patients in the later stages of the disease. In 2006, the FDA also approved Sanofi’s other other enzyme replacement therapy, Myozyme, to also treat Pompe disease, in addition to their Lumizyme, approved in 2010 for late-onset of Pompe disease.
Read more here.